Clinical Trial

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Protocol Amendment History 2 changes
notable Trial sites expanded: 3 -> 13 locations 2026-07-16
critical Recruitment opened 2026-04-25
Trial Details
NCT Number NCT07446322
Lead Sponsor Oncolytics Biotech
Conditions Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Enrollment 60 participants
Start Date 2026-04-30
Primary Completion 2027-08-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15